Scholarlink

Purpose <p>Patients with cancer commonly access cannabis hoping to relieve their symptoms. This study assessed whether a 1:1 10&#xa0;mg/ml THC:CBD combination oil could improve total symptom burden in patients with advanced cancer over that provided by palliative care alone.</p> Methods <p>Participants were randomised to medicinal cannabis (MC) or placebo oil; dose escalated over 14&#xa0;days according to tolerance and efficacy and continued to day 28. Symptoms assessed using the Edmonton Symptom Assessment Scale (ESAS) were summated to give a total symptom distress score (TSDS). The primary outcome measure was the change from baseline in TSDS at day 14. Secondary outcomes included individual symptom scores, opioid use, participant-selected dose, QoL, psychological symptoms, global impression of change (GIC), and adverse effects.</p> Results <p>The pre-planned sample size of 120 at day 14 was reached following the randomisation of 144 patients. Mean (SD) TSDS improved over time in both arms (− 6.30 (12.3) MC, − 6.98 (12.56) placebo, <i>p</i> = 0.76) to day 14 with no difference between arms. A statistically significant improvement in ESAS pain scores in the MC arm (mean (SD) − 1.42 (2.15) MC and − 0.46 (2.83) placebo, <i>p</i> = 0.04) was at the expense of greater psychomimetic toxicity. Improvement in general well-being was greater for the placebo. GIC and the pain component of QoL both favoured MC.</p> Conclusions <p>Patients can be informed that a 1:1 THC:CBD combination cannabis oil was no better than palliative care alone in palliating symptoms in patients with advanced cancer. A small benefit in pain control was associated with greater toxicity.</p> Trial registration <p>Australian New Zealand Clinical Trial Registry (ANZCTR): ACTRN12619000037101, 14/01/2019.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月24日

查看全文
  • Janet R. Hardy,
  • Ristan M. Greer,
  • Anita M. Pelecanos,
  • Georgie E. Huggett,
  • Alison M. Kearney,
  • Taylan H. Gurgenci,
  • Phillip D. Good

摘要

Purpose

Patients with cancer commonly access cannabis hoping to relieve their symptoms. This study assessed whether a 1:1 10 mg/ml THC:CBD combination oil could improve total symptom burden in patients with advanced cancer over that provided by palliative care alone.

Methods

Participants were randomised to medicinal cannabis (MC) or placebo oil; dose escalated over 14 days according to tolerance and efficacy and continued to day 28. Symptoms assessed using the Edmonton Symptom Assessment Scale (ESAS) were summated to give a total symptom distress score (TSDS). The primary outcome measure was the change from baseline in TSDS at day 14. Secondary outcomes included individual symptom scores, opioid use, participant-selected dose, QoL, psychological symptoms, global impression of change (GIC), and adverse effects.

Results

The pre-planned sample size of 120 at day 14 was reached following the randomisation of 144 patients. Mean (SD) TSDS improved over time in both arms (− 6.30 (12.3) MC, − 6.98 (12.56) placebo, p = 0.76) to day 14 with no difference between arms. A statistically significant improvement in ESAS pain scores in the MC arm (mean (SD) − 1.42 (2.15) MC and − 0.46 (2.83) placebo, p = 0.04) was at the expense of greater psychomimetic toxicity. Improvement in general well-being was greater for the placebo. GIC and the pain component of QoL both favoured MC.

Conclusions

Patients can be informed that a 1:1 THC:CBD combination cannabis oil was no better than palliative care alone in palliating symptoms in patients with advanced cancer. A small benefit in pain control was associated with greater toxicity.

Trial registration

Australian New Zealand Clinical Trial Registry (ANZCTR): ACTRN12619000037101, 14/01/2019.